Compare Unilever plc (UL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs Viatris Inc — how do they compare? Unilever plc trades at $61.75 (market cap $134.06B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Unilever plc is far larger — about 7.2× Viatris Inc's market cap, and Unilever plc pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| UL | VTRS | |
|---|---|---|
Market Cap | $134.06B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $17.86 |
52-Week Low | $55.05 | $9.49 |
Enterprise Value | $159.86B | $30.80B |
Dividend Yield | 3.65% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $61.75, down 1.77% with bearish technical signals. The company reported strong Q2 2026 results with 5.8% underlying sales growth - the strongest in a decade - prompting a raised full-year outlook. Despite recent earnings misses, UL maintains robust profitability with 18.75% net margins and 53.32% ROE. The pending $65 billion McCormick merger and potential Thorne acquisition signal strategic expansion.
UL presents a mixed outlook with strong fundamentals offset by recent underperformance. The merger potential offers growth catalysts, but consecutive earnings misses and bearish technicals warrant caution. Analyst consensus leans neutral (51% Hold) with balanced buy/sell ratings. Key risks include integration challenges and competitive pressures in consumer goods.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
